{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer+%28Advanced%2FMetastatic%29&page=2", "query": { "condition": "Breast Cancer (Advanced/Metastatic)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 814, "total_pages": 82, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer+%28Advanced%2FMetastatic%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer+%28Advanced%2FMetastatic%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T07:57:29.542Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00087958", "title": "Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "XRP9881", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2004-08", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2009-05-01", "last_synced_at": "2026-10-14T07:57:29.542Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00087958" }, { "nct_id": "NCT03767335", "title": "MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "MEN1611", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Menarini Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2018-11-13", "completion_date": "2024-02-23", "has_results": true, "last_update_posted_date": "2025-06-26", "last_synced_at": "2026-10-14T07:57:29.542Z", "location_count": 3, "location_summary": "Fort Lauderdale, Florida • Farmington Hills, Michigan • St Louis, Missouri", "locations": [ { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Farmington Hills", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03767335" }, { "nct_id": "NCT01964924", "title": "Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor Negative", "HER2/Neu Negative", "Invasive Breast Carcinoma", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Stage IV Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Akt Inhibitor GSK2141795", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2013-10-02", "completion_date": "2018-04-23", "has_results": true, "last_update_posted_date": "2019-09-20", "last_synced_at": "2026-10-14T07:57:29.542Z", "location_count": 8, "location_summary": "Washington D.C., District of Columbia • Tampa, Florida • Buffalo, New York + 4 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Buffalo", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01964924" }, { "nct_id": "NCT05382286", "title": "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple Negative Breast Cancer", "PD-L1 Positive" ], "interventions": [ { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 443, "start_date": "2022-07-25", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2025-09-18", "last_synced_at": "2026-10-14T07:57:29.542Z", "location_count": 247, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 175 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05382286" }, { "nct_id": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "FT538", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Monoclonal antibody - Dose Escalation", "type": "COMBINATION_PRODUCT" }, { "name": "Monoclonal antibody - Dose Expansion", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2021-10-15", "completion_date": "2023-08-11", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-14T07:57:29.542Z", "location_count": 4, "location_summary": "Hackensack, New Jersey • Nashville, Tennessee • Houston, Texas + 1 more", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05069935" }, { "nct_id": "NCT00471276", "title": "Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 83, "start_date": "2007-08", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2011-07-25", "last_synced_at": "2026-10-14T07:57:29.542Z", "location_count": 31, "location_summary": "Bakersfield, California • Burbank, California • Fountain Valley, California + 24 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Hawthorne", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00471276" }, { "nct_id": "NCT00274469", "title": "A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "fulvestrant", "type": "DRUG" }, { "name": "anastrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "45 Years to 100 Years · Female only" }, "enrollment_count": 205, "start_date": "2006-02-06", "completion_date": "2017-01-13", "has_results": true, "last_update_posted_date": "2019-09-06", "last_synced_at": "2026-10-14T07:57:29.542Z", "location_count": 5, "location_summary": "Frederick, Maryland • St Louis, Missouri • Teaneck, New Jersey + 2 more", "locations": [ { "city": "Frederick", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Teaneck", "state": "New Jersey" }, { "city": "Austin", "state": "Texas" }, { "city": "Duncanville", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00274469" }, { "nct_id": "NCT03858972", "title": "Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Tesetaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Odonate Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2019-02-05", "completion_date": "2021-06-11", "has_results": false, "last_update_posted_date": "2021-07-30", "last_synced_at": "2026-10-14T07:57:29.542Z", "location_count": 9, "location_summary": "Whittier, California • Lakewood, Colorado • Fort Myers, Florida + 6 more", "locations": [ { "city": "Whittier", "state": "California" }, { "city": "Lakewood", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03858972" }, { "nct_id": "NCT06982521", "title": "Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "PIK3CA Mutation", "HER2- Negative Breast Cancer", "Hormone Receptor Positive Tumor", "Breast Cancer", "Metastatic Breast Cancer", "Advanced Breast Cancer" ], "interventions": [ { "name": "Zovegalisib", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Relay Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2025-08-26", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-14T07:57:29.542Z", "location_count": 52, "location_summary": "Gilbert, Arizona • Beverly Hills, California • Duarte, California + 42 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06982521" }, { "nct_id": "NCT00347919", "title": "Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "pazopanib (GW786034) 400 mg", "type": "DRUG" }, { "name": "lapatinib (GW572016) 1500 mg", "type": "DRUG" }, { "name": "lapatinib (GW572016) 1000 mg", "type": "DRUG" }, { "name": "pazopanib (GW786034) 800 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 189, "start_date": "2006-07", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2016-02-25", "last_synced_at": "2026-10-14T07:57:29.542Z", "location_count": 19, "location_summary": "Jonesboro, Arkansas • Alhambra, California • Bakersfield, California + 16 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00347919" } ] }